Clinical Observation of Apatinib Combined with Icotinib in the Treatment of EGFR Gene Exon 21 L858R Mutant NSCLC
Objective To investigate the clinical effect of apatinib combined with icotinib in the treatment of epidermal growth factor receptor(EGFR)gene exon 21 L858R mutant non-small cell lung cancer(NSCLC).Methods 101 patients with EGFR gene exon 21 L858R mutant NSCLC were divided into the observation group(n =51)and the control group(n =50)by random number table method.The observation group was treated with apatinib combined with icotinib,and the control group was treated with icotinib for 56 days(2 cycles).Short-term efficacy and adverse reactions were compared between the 2 groups.Long-term efficacy in the 2 groups was analyzed using the K-M survival analysis curve.Results There was no statistically significant difference between the observation group and the control group in terms of the objective response rate(ORR)(74.51%vs.74.00%)and disease control rate(DCR)(92.16%vs.94.00%)(P>0.05).No adverse reactions above grade2 were observed in either group.The incidence rates of hypertension and proteinuria in the observation group(52.94%and 50.98%)were higher than those in the control group(16.00%and 10.00%)(P<0.05).The survival rate in the observation group was significantly higher than that in the control group(69.3%vs.43.1%)(P<0.05).Conclusion Applying apatinib combined with icotinib to treat patients with EGFR gene exon 21 L858R mutant NSCLC can prolong their progression free survival time,and the adverse re-actions are acceptable.
万方数据
维普
